Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes

JAMA

Volumn 308, Issue 9, 2012, Pages 882-889

  Andersson, Charlotte ^a   Lyngbæk, Stig ^a   Nguyen, Cu Dinh ^a   Nielsen, Mia ^a   Gislason, Gunnar H ^a   Køber, Lars ^a   Torp Pedersen, Christian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO; PRASUGREL; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TICAGRELOR; WARFARIN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TREATMENT RESPONSE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; DENMARK; INFORMATION PROCESSING; MIDDLE AGED; PATHOPHYSIOLOGY; REGISTER; RISK; STATISTICS; THROMBOCYTE ACTIVATION;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DATA COLLECTION; DENMARK; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RISK; TICLOPIDINE;

EID: 84865701469     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/2012.jama.10779     Document Type: Article

References (29)

1. Andersson C, Gislason GH, Mérie C, et al. Long-term prognostic importance of diabetes after a myocardial infarction depends on left ventricular systolic function. Diabetes Care. 2011;34(8):1788-1790.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234. (Pubitemid 28350165)
3. Norgaard ML, Andersen SS, Schramm TK, et al. Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction - a nationwide study. Diabetologia. 2010;53(8):1612-1619.
4. Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117(15):1945-1954. (Pubitemid 351543470)
5. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798-813.
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8):2430-2435. (Pubitemid 41134272)
7. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007;115(6):708-716. (Pubitemid 46294761)
8. Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50(16):1541-1547. (Pubitemid 47532327)
9. Bhatt DL, Fox KA, Hacke W, et al CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
10. Steinhubl SR, Berger PB, Mann JT III, et al CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411-2420. (Pubitemid 35340537)
11. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. (Pubitemid 32758501)
12. Wiviott SD, Braunwald E, McCabe CH, et al TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. (Pubitemid 350106708)
13. Wallentin L, Becker RC, Budaj A, et al PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
14. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003;56(2):124-130. (Pubitemid 36315938)
15. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445-448. (Pubitemid 27382061)
16. Sørensen R, Abildstrøm SZ, Hansen PR, et al. Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. J Am Coll Cardiol. 2011;57(10):1202-1209.
17. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol. 2001;37(4):992-997. (Pubitemid 32217595)
18. Kümler T, Gislason GH, Kirk V, et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail. 2008;10(7):658-660.
19. Andersson C, Norgaard ML, Hansen PR, et al. Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study. Eur J Heart Fail. 2010;12(12):1333-1338.
20. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97(12):1759-1764. (Pubitemid 43817867)
21. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967-1974.
22. Sørensen R, Abildstrom SZ, Weeke P, et al. Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study. BMC Cardiovasc Disord. 2010;10(1):6.
23. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST- Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):1920-1959.
24. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205-2241.
25. Wiviott SD, Braunwald E, Angiolillo DJ, et al TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626-1636.
26. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166-1173.
27. Hamm CW, Bassand JP, Agewall S, et al ESC Committee for Practice Guidelines; Document Reviewers. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054.
28. Wiviott SD, Trenk D, Frelinger AL, et al PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high-loading and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923-2932. (Pubitemid 350291199)
29. Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA. 2012;307(23):2495-2496.